Clinical Trial Update: A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the benefit of RUCONEST® in subjects with adverse events related to IVIG infusions in common variable immunodeficiency (CVI).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Sponsor: IMMUNOe Research Centers | Conditions: CVI - Common Variable Immunodeficiency | Phase 4 | Status: COMPLETED